Sapient Capital’s AstraZeneca AZN Stock Holding History

Sapient Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	8,592 +4,962	+137%	+$933K	0.02%	166
2026 Q1	$703K	Buy	3,630 +1,730	+91%	+$334K	0.01%	232
2025 Q4	$352K	Buy	+1,900	New	+$333K	﹤0.01%	316

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sapient Capital's AZN Position: Q2 2026 in Review

Sapient Capital increased its AstraZeneca (AZN) stake by 137% in Q2 2026, buying an estimated $933K and bringing the position to 8,592 shares worth $1.61M. The position accounts for 0.02% of the portfolio, ranked #166.

Sapient Capital first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Sapient Capital held 8,592 shares of AstraZeneca worth $1.61M as of Q2 2026.
Sapient Capital bought 4,962 AstraZeneca shares in Q2 2026, an estimated $933K.
AstraZeneca made up 0.02% of Sapient Capital's portfolio in Q2 2026, its #166 holding.
Sapient Capital first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.